Verastem/$VSTM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Verastem

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Ticker

$VSTM
Sector
Primary listing

Employees

78

Verastem Metrics

BasicAdvanced
$530M
-
-$3.52
0.83
-

What the Analysts think about Verastem

Analyst ratings (Buy, Hold, Sell) for Verastem stock.

Bulls say / Bears say

The U.S. FDA granted accelerated approval for AVMAPKI™ FAKZYNJA™ as the first-ever treatment for KRAS-mutated recurrent low-grade serous ovarian cancer, establishing a new therapy for this rare disease.
AVMAPKI FAKZYNJA CO-PACK recorded $2.1 million in net product revenue in its first six weeks, showing strong early sales momentum.
Verastem finished Q2 2025 with $164.3 million in cash and cash equivalents, providing enough funding to support operations into the second half of 2026 and flexibility to advance trials.
Verastem reported a net loss of $25.93 million in Q2, mainly due to higher R&D and administrative spending, which delays profitability.
Operating expenses totaled $45.90 million in Q2, far outpacing net product revenue of $2.1 million, showing a significant burn rate during commercial launch.
With $164.3 million in cash only covering operations until the second half of 2026, Verastem may need additional funding or could face dilution risk if future trial results or revenue don't meet expectations.
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.

Verastem Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Verastem Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VSTM

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs